Labcorp Launches Blood Test for Risk Assessment and Clinical Management of Preeclampsia
The test measures angiogenic biomarkers associated with preeclampsia, serum soluble fms-like tyrosine kinase 1 and placental growth factor.
Read MorePosted by Andy Lundin | Jan 31, 2024 | Womens Health |
The test measures angiogenic biomarkers associated with preeclampsia, serum soluble fms-like tyrosine kinase 1 and placental growth factor.
Read MorePosted by Chris Wolski | Nov 21, 2023 | Company News |
Labcorp announced the completion of a laboratory agreement with Legacy Health to acquire select assets of Legacy’s outreach lab business.
Read MorePosted by Andy Lundin | Nov 15, 2023 | Colorectal, Company News |
Geneoscopy’s multi-target stool RNA (mt-sRNA) biomarker panel is designed to detect precancerous lesions and colorectal cancer.
Read MorePosted by Andy Lundin | Oct 16, 2023 | Dementias & Alzheimer’s |
Labcorp’s blood-based test combines three blood biomarkers to identify and assess biological changes associated with Alzheimer’s disease.
Read MorePosted by Chris Wolski | Aug 24, 2023 | Company News |
Labcorp has announced an agreement with Tufts Medicine for Labcorp to acquire the Tufts Medicine outreach laboratory business.
Read More